Aclarion, Inc.

NasdaqCM ACON

Aclarion, Inc. Price to Sales Ratio (P/S) on February 06, 2025

Aclarion, Inc. Price to Sales Ratio (P/S) is NA on February 06, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Aclarion, Inc. 52-week high Price to Sales Ratio (P/S) is NA on February 06, 2025, which is NA below the current Price to Sales Ratio (P/S).
Aclarion, Inc. 52-week low Price to Sales Ratio (P/S) is NA on February 06, 2025, which is NA below the current Price to Sales Ratio (P/S).
Aclarion, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is NA.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: ACON

Aclarion, Inc.

CEO	Mr. Brent Ness
IPO Date	April 22, 2022
Location	United States
Headquarters	951 Mariners Island Boulevard
Employees	4
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Database Medical Instruments Pharmaceuticals Software-as-a-Service (SaaS) Telehealth

Description

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Key trends

Past 5 years